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Abstract Disruption of Bruton’s tyrosine kinase (BTK) func-
tion leads to x-linked immunode¢ciency (xid) in mice. BTK-
de¢cient (btk3/3) B cells are defective for survival. Prior studies
show that BTK is required for the induction of Bcl-xL following
B cell antigen receptor (BCR) engagement. However, the mech-
anism underlying Bcl-xL induction in response to BCR ligation
remains unresolved. We now demonstrate that BTK regulates
bcl-x expression by transcriptional control in response to BCR
engagement. BTK targets nuclear factor-UB (NF-UB) to acti-
vate the bcl-x promoter via a phospholipase C-Q2 (PLC-Q2)-de-
pendent mechanism. Perturbation of the BTK/PLC-Q2/NF-UB
signaling axis likely contributes to the defective expression of
bcl-x and compromised survival of xid B cells.
/ 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The B cell antigen receptor (BCR) transmits biochemical
signals via the activation of protein tyrosine kinases (PTK)
including the cytoplasmic PTKs Lyn, Syk, and BTK (Bruton’s
tyrosine kinase) [1^3]. Of these, naturally occurring mutations
in the btk gene cause the B cell de¢ciency disorders X-linked
agammaglobulinemia in humans and x-linked immunode¢-
ciency (xid) in mice [4,5]. Xid B cells undergo apoptosis in-
stead of proliferation in response to BCR stimulation [6^8],
suggesting a defect in survival and cell cycle progression [7,9].
Although prior studies demonstrate that xid B cells fail to
increase the levels of pro-survival protein Bcl-xL upon BCR
stimulation [6,8], the role of BTK in this response remains
largely unde¢ned.
In response to BCR stimulation, BTK phosphorylates and
activates phospholipase C-Q2 (PLC-Q2) [10,11]. Active PLC-Q2
hydrolyzes phosphatidylinositol 4,5-bisphosphate, producing
the two lipid second messengers, inositol 1,4,5-triphosphate
and diacylglycerol. These second messengers trigger calcium
and protein kinase C signaling modulating transcription fac-
tors and their target genes [12,13]. We have recently demon-
strated that BTK is critical in the BCR-directed nuclear trans-
location of nuclear factor-UB (NF-UB) via a PLC-Q2/IUB
kinase (IKK)-dependent pathway [14]. However, the signi¢-
cance of this signaling axis in the BCR-responsive modulation
of gene expression remains unclear. It is also not known
whether BCR executes this e¡ect by directing bcl-x transcrip-
tion or enhancing the post-translational stability of Bcl-xL. In
keeping with the established link between BTK, PLC-Q2 and
NF-UB, we asked whether BTK facilitates Bcl-xL induction at
the level of transcription. Here we demonstrate that BTK and
PLC-Q2 regulate bcl-x expression via NF-UB following BCR
engagement.
2. Materials and methods
2.1. Mice, cells, and reagents
The generation of btk-de¢cient mice (null mutant; btk3=3) has been
described previously [15]. The chicken DT40 cell line and DT40 cells
de¢cient for BTK or PLC-Q2 [10,16] were kind gifts of Dr. Tomohiro
Kurosaki (Riken Cell Bank, Japan). Primary B lymphocytes were
puri¢ed by AutoMACS (Miltyni Biotech) by a negative selection pro-
tocol, cultured, and stimulated as described [14,17]. The purity of B
cells isolated in this manner was approximately 90^95% as veri¢ed by
£uorescence-activated cell sorting (FACS) analysis using anti-B220
and anti-IgM antibodies (Pharmingen, San Diego, CA, USA). Except
where indicated, DT40 and primary mouse B cells were stimulated
with anti-chicken IgM monoclonal antibody (M4) and goat anti-
mouse IgM respectively or phorbol myristate acetate (PMA) and ion-
omycin 1 WM each (Calbiochem-Novabiochem, La Jolla, CA, USA).
For the pharmacological inhibition of NF-UB, cells were incubated
with the indicated concentrations of pyrrolidine dithiocarbamate
(PDTC, Sigma, St. Louis, MO, USA) and anti-IgM antibodies.
FITC-anti-Bcl-XL, FITC-IgG3 isotype control and PE-anti-B220 anti-
bodies were purchased from Pharmingen and anti-phospho-IKK from
Cell Signaling (Beverly, MA, USA).
2.2. Northern blotting analyses
For Northern analysis of bcl-x mRNA, 20U107 splenocytes were
activated for 8 h at 37‡C and total RNA was extracted via tri-Pure
Reagent (Boehringer Mannheim, Indianapolis, IN, USA). 10 Wg of
RNA was subjected to Northern blotting and hybridized with an
K[32p]CTP-labeled probe consisting of a 0.6 kb fragment of murine
bcl-x cDNA (Gift of A. Ma, University of Chicago, Chicago, IL,
USA). The blots were exposed to a phosphoimager plate for signal
quanti¢cation. The blot was then stripped and reprobed with a
K[32p]CTP-labeled probe murine CW cDNA.
2.3. Western blotting analyses
For Bcl-xL studies whole cell extracts were resolved by 12% SDS^
PAGE, and blotted on to Immobilon (Millipore, Bedford, MA, USA)
membranes as described [14,17]. The membranes were probed with
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rabbit anti-Bcl-xL (BD Transduction Labs, Cockeysville, MD, USA)
or anti-Bcl-2 (Santa Cruz, Santa Cruz, CA, USA). For IUBK degra-
dation assays, 4U106 cells/sample were preincubated for 30 min in
medium containing 10 WM cycloheximide and various concentrations
of PDTC, then stimulated as indicated. Cell extracts were resolved by
SDS^PAGE as described [14]. For IKK phosphorylation, whole cell
extracts were resolved by 8% SDS^PAGE, and blotted on to Immo-
bilon membranes as described [14,17]. The membranes were probed
with rabbit anti-phospho-IKK antibodies that recognize phosphory-
lated Ser 180 and Ser 181 in IKKK and IKKL respectively (Cell
Signaling Technology) or anti-Bcl-2 (Santa Cruz). The bound anti-
bodies were revealed by horseradish peroxidase-conjugated goat
anti-rabbit antibodies and detected by enhanced chemiluminescent
detection (Pierce, Rockford, IL, USA) on autoradiography ¢lm.
2.4. FACS
For £ow cytometric analyses (FACS) of Bcl-xL protein levels, sple-
nocytes were activated for 24 h in the presence of anti-IgM. 1U106
cells/sample were stained for surface expression of B220 and intra-
cellular levels of Bcl-xL was achieved by with FITC-conjugated anti-
Bcl-xL antibodies in the presence of Fix and Perm (Caltag Labs).
Samples were stained in parallel with a FITC-conjugated IgG3 anti-
body as a background control. Samples were assayed on a FACStar1
£uorescent cell sorter and the data was analyzed using CELLQuest1
software (Becton Dickinson, Cockeysville, MD, USA).
2.5. Plasmid constructs and luciferase assays
Reporter plasmids containing 0.6 or 1.2 kb of the mouse bcl-x
promoter fused to a ¢re£y luciferase gene (BclxLuc0.6/BclxLuc1.2)
were the kind gift of G. Nunez. Additionally, a NF-UB reporter plas-
mid encoding ¢re£y luciferase under the control of a NF-UB-respon-
sive promoter (6 UB), a Renilla luciferase control and a dominant-
negative IUBK (IUBKss=aa) expression vector were [14,17] cotransfected
with indicated plasmids into 1U107 DT40 cells and analyzed for lu-
ciferase activity 6 h after treatment with anti-IgM or PMA/ionomycin
as described [14,17].
3. Results
3.1. BTK is critical for BCR-responsive induction of
bcl-x mRNA
To begin to de¢ne the molecular mechanisms underlying
defective induction of Bcl-xL protein in btk3=3 B cells, we
analyzed bcl-x mRNA levels in BCR-stimulated cells. North-
ern analyses showed that BCR crosslinking results in a sig-
ni¢cant increase in the steady state levels of bcl-x transcript in
wild type but not btk3=3 B cells (Fig. 1, upper panel, compare
lanes 1 and 2 with 5 and 6). The failure of btk3=3 B cells to
induce bcl-x transcription following stimulation via the BCR
is not due to an intrinsic defect in bcl-x gene expression, as
stimulation via CD40 or pharmacological agents PMA and
ionomycin induced similar levels of the bcl-x transcript in
both btk3=3 and wild type B cells (compare lanes 1 and 5
with 7 and 8). These results indicate that BTK is essential
for BCR-responsive induction of bcl-x mRNA suggesting
that BTK signaling pathways may directly regulate Bcl-xL
protein levels.
3.2. Inhibition of NF-UB prevents BCR-directed increases in
Bcl-xL
To elucidate the mechanism by which BTK regulates bcl-x
levels, we investigated whether inhibition of BCR-induced
NF-UB blocks bcl-x expression. The e¡ect of the selective
NF-UB inhibitor PDTC [18^20] on BCR-responsive bcl-x ex-
pression was examined. PDTC blocked BCR-directed Bcl-xL
protein induction as determined by FACS or Western blotting
(Fig. 2A,B). To ascertain that PDTC inhibited the NF-UB
pathway, we assayed for the BCR-directed degradation of
the NF-UB inhibitor IUBK, a required step in the activation
of this transcription factor. Consistent with its proposed in-
hibitory function at the proteasome level, PDTC blocked
BCR-induced degradation of IUBK (Fig. 2C). In contrast,
PDTC did not block BCR-induced phosphorylation of
IKKK and L which lie directly upstream of IUBK in NF-UB
pathway (Fig. 2D). These experiments suggest that in primary
B cells NF-UB regulates bcl-x expression following activation
via the BCR.
3.3. BTK, PLC-Q2, and NF-UB are required for activation of
the bcl-x promoter
To extend our ¢ndings, we investigated whether the BTK/
NF-UB signaling axis targets the bcl-x promoter directly. BCR
stimulation resulted in a two-fold increase in bcl-x promoter
activity in DT40 (Fig. 3, lane 1) but not in cells de¢cient for
either BTK or PLC-Q2 (lanes 2 and 3). This activity was com-
pletely restored in DT40.BTK cells reconstituted with human
BTK cDNA (DT40.BTKR) or DT40.PLC-Q2 reconstituted
with human PLC-Q2 cDNA (DT40.PLC-Q2R), indicating
that BTK and PLC-Q2 expression are necessary for BCR-di-
rected transcription of the bcl-x reporter gene (lanes 4 and 5).
Furthermore, PMA and ionomycin induced similar levels of
reporter expression in all cell types, indicating that down-
stream signaling pathways are intact and function indepen-
dently of BTK and PLC-Q2.
To test whether NF-UB is functionally important for BCR-
responsive transcription of bcl-x, DT40 cells were cotrans-
fected with the bcl-x reporter plasmid and an expression con-
struct encoding a dominant negative form of the NF-UB in-
hibitor IUBK (IUBKser32=36ala), which has been demonstrated to
block nuclear translocation of NF-UB [21]. Consistent with
our hypothesized role for NF-UB in BCR-directed transcrip-
tion of bcl-x, ectopic expression of IUBKser32=36ala completely
blocked both BCR- and PMA/ionomycin-directed activation
Fig. 1. BCR-responsive expression of bcl-x mRNA is BTK-depen-
dent. Northern analysis of RNA extracted from splenocytes isolated
from wild type or btk3=3 mice. Cells were either left unstimulated
(lanes 1 and 5) or activated for 8 h with 10 Wg/ml anti-mouse IgM
F(abP)2 (lanes 2 and 6), 10 Wg/ml anti-mouse CD40 antibodies (lanes
3 and 7), or PMA/ionomycin (lanes 4 and 8). 10 Wg of total RNA
from each sample was used in Northern analyses with K[32p]CTP-la-
beled murine bcl-x cDNA as a probe (upper panel). The blot was
stripped and reprobed with a K[32p]CTP-labeled murine CW cDNA
probe to verify the integrity and quantity of B cell RNA in each
sample (lower panel).
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of the bcl-x reporter gene (Fig. 3, lane 6). This result impli-
cates the BCR-directed activation of NF-UB in the transcrip-
tional activation of the bcl-x promoter.
4. Discussion
We have previously reported a requirement for BTK in the
BCR-directed activation of NF-UB [17]. Furthermore, we and
others have identi¢ed functional NF-UB binding sites in the
bcl-x promoter [22,23]. As such, we hypothesized that BTK-
dependent activation of NF-UB may promote BCR-responsive
transactivation of bcl-x. Here we demonstrate that in response
to BCR signaling BTK mediates Bcl-xL induction by targeting
NF-UB to bcl-x promoter. This ¢nding is consistent with a
role for NF-UB in bcl-x regulation in response to CD40 liga-
tion [23]. Furthermore, these data validate our hypothesis at
multiple levels. First, BTK is indeed required for BCR-di-
rected transcriptional activation of bcl-x (Fig. 1). Second, a
BTK substrate PLC-Q2 that we previously showed to be es-
sential for NF-UB activation is also required for bcl-x pro-
moter activity (Fig. 3). Third, pharmacological inhibition of
BCR-induced NF-UB interferes with bcl-x expression (Fig. 2).
Fourth, a dominant negative inhibitor of NF-UB (IUBKss=aa)
completely blocks BCR-dependent activation of bcl-x pro-
moter (Fig. 3). Together these ¢ndings provide mechanistic
insights as to the necessary role for BTK signal transducers
(PLC-Q2 and NF-UB) in the transcriptional regulation of bcl-
x, explaining in part why xid B cells are impaired in BCR-
directed Bcl-xL induction. Interference with this survival
mechanism caused by loss of BTK function may also explain
the paucity of mature B cells observed in xid mice.
Isotype Control
Non-Stimulated
Anti-IgM
Anti-IgM+ 0.25 µM PDTC
Anti-IgM+ 0.50 µM PDTC
Fig. 2. The NF-UB inhibitor PDTC blocks BCR-induced Bcl-xL production. A: FACS analysis of Bcl-xL in B cells activated with 20 Wg/ml
anti-IgM for 24 h in the presence or absence of PDTC. Expression of Bcl-xL in B220þ B cells is displayed. B: Puri¢ed splenic B cells (95% as
determined by FACS) were incubated with or without 20 Wg/ml of anti-IgM and PDTC for 16 h and total cellular extracts (13 Wg/lane) were
analyzed by SDS^PAGE immunoblotting. The blots were probed sequentially with anti-Bcl-xL (top panel) and anti-Bcl-2 for protein loading
control (bottom panel). C: PDTC interferes with IUBK degradation. Cells were preincubated with cycloheximide (to arrest protein synthesis)
and PDTC for 30 min prior to stimulation as indicated. Cellular extracts were analyzed by Western blotting. The blots were probed with anti-
IUBK, stripped and reprobed with anti-p38 antibodies to verify the protein content and integrity. D: PDTC does not prevent BCR-induced
IKK phosphorylation. Western blot analysis of protein extracts from B cells treated as indicated. Blots were probed sequentially with anti-phos-
pho-speci¢c IKKK and L and anti-p38 for protein content and integrity.
Fig. 3. BTK, PLC-Q2, and NF-UB are required for BCR-directed
transcription from the bcl-x promoter. DT40 chicken B cells and
DT40 cells de¢cient for BTK (DT40.BTK) or PLC-Q2 (DT40.PLC-
Q2) or DT40.BTK cells reconstituted with human BTK cDNA
(DT40.BTKR) or DT40.PLC-Q2 cells reconstituted with human
PLC-Q2 cDNA (DT40.PLC-Q2R) (1U107 B cells/sample) were co-
transfected with 15 Wg of a plasmid containing the ¢re£y luciferase
gene downstream of a 1.2 kb region of the murine bcl-x promoter
(Bcl-xLuc1.2) and 1 Wg of a Renilla luciferase expression vector to
normalize for transfection e⁄ciency. Also, 1U107 DT40 cells were
transfected with the addition of 6 Wg of a dominant-negative IUBK
expression vector (DT40/IUBKss=aa). Cells were incubated for 18 h
post-transfection and activated for 6 h with anti-IgM or PMA/iono-
mycin (P/I). Cytoplasmic extracts were obtained and luciferase was
quanti¢ed. Results are reported as the mean fold induction of lucif-
erase in stimulated relative to unstimulated cells. Data are represen-
tative of three experiments.
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Our results mirror those presented in a prior study describ-
ing a role for NF-UB in the negative regulation of bcl-x in
CD4þ/CD8þ double positive thymocytes isolated from trans-
genic mice harboring a dominant negative form of IUBK [24].
However, Bcl-xL levels were not a¡ected in transgenic thymo-
cytes stimulated via the T cell antigen receptor. In contrast,
data presented here demonstrate positive regulation of the bcl-
x gene by NF-UB in both primary B cells and an immature B
cell line (DT40, Figs. 1 and 3). This positive regulation of the
bcl-x promoter by NF-UB is further supported by our obser-
vation that overexpression of Rel subunits is su⁄cient to drive
transcription of a luciferase gene under bcl-x promoter control
in vitro (data not shown). Within lymphocytes, bcl-x gene
transcription is thus likely to be regulated in a tissue- and
stage-speci¢c manner. Our observations regarding bcl-x ex-
pression in B cells are consistent with the recent ¢ndings
that B cells isolated from mice de¢cient for NF-UB subunits
c-Rel or RelA or express a dominant inhibitor of NF-UB dis-
play defects in BCR-directed survival and proliferation similar
to those of btk3=3 B cells [25^28]. Thus, a block in BTK-
dependent NF-UB activation impairs BCR-directed induction
of bcl-x transcription, likely contributing to the compromised
survival and proliferation of xid B cells. Although it is likely
that NF-UB cooperates with other transcription factors to
promote bcl-x gene expression, the BTK/PLC-Q2/NF-UB de-
pendence of bcl-x transcription reveals a critical and non-re-
dundant role for NF-UB in this activity.
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